NCT04696432已完成1 期
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2020年11月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Incidence and severity of adverse events (AE)
研究概览
简要总结
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
详细描述
This is a single-arm, open label, phase I study to evaluate the safety and preliminary efficacy of C-CAR039 in adults with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. 10 patients are planned to be enrolled. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of C-CAR039. Following manufacture of the drug product, subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide prior to C-CAR039 infusion. All subjects who have received C-CAR039 infusion will be followed for up to 24 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-70 years (include 18 and 70), male or female;
- •Expected survival ≥ 12 weeks
- •ECOG score 0-2
- •CD19 or CD20 positive B-NHL confirmed by cytology or histology according to WHO2016 criteria, including DLBCL, PMBCL, tFL, FL and MCL;
- •Relapsed or refractory disease after ≥ 2 lines (for FL, at least 3 lines) of standard therapy or relapsed after autologous stem cell transplantation (ASCT)
- •For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause of intolerance should be recorded;
- •No contraindications of apheresis.
- •At least one measurable lesion according to Lugano 2014 criteria;
- •Adequate organ and bone marrow function.
- •The patient volunteered to participate in the study and signed the Informed Consent;
排除标准
- •Malignant tumors other than B-NHL within 5 years prior to screening, except cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery;
- •Active HIV, HBV, HCV or treponema pallidum infection ;
- •Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy;
- •Any uncontrolled active disease that prevents participation in the trial
- •Any situation that the investigator believes will harm the safety of the subjects or interfere with the purpose of the study
- •Female subjects who have been pregnant or breastfeeding, or who plan to conceive during or within 1 year after treatment, or male subjects' partner plans to conceive within 1 year after C-CAR039 infusion;
- •Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;
- •Patients who have been previously infected with tuberculosis;
- •Administered Corticosteroids and/or other immunosuppressants within 7 days before apheresis. and 5 days before the infusion of C-CAR039;
- •Patients with central nervous system involvement;
- •Any systemic antitumor therapy performed within 2 weeks before enrollment;
- •Those with medical conditions that prevent them from signing the written informed consent or from complying with the study procedures; or those who are unwilling or unable to comply with the study requirements;
- •Other conditions was considered unsuitable for enrollment by the investigator.
研究组 & 干预措施
Prizloncabtagene autoleucel
Experimental
Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.
干预措施: Prizloncabtagene autoleucel (Biological)
结局指标
主要结局
Incidence and severity of adverse events (AE)
时间窗: Up to 24 months after C-CAR039 infusion
Incidence and severity of adverse events, including AE, Serious AE, AE of special interset (AESI)
次要结局
- Overall Response rate (ORR)(Up to 24 Months after C-CAR039 infusion)
- Maximum concentration of C-CAR039 in the peripheral blood (Cmax)(Up to 24 Months after C-CAR039 infusion)
- AUC0-28d of C-CAR039 in the peripheral blood (AUC0-28d)(Up to 28 days after C-CAR039 infusion)
- Time to reach the maximum plasma concentration (Tmax)(Up to 24 Months after C-CAR039 infusion)
- Duration of response (DOR)(Up to 24 Months after C-CAR039 infusion)
- Progression-free survival (PFS)(Up to 24 Months after C-CAR039 infusion)
- Overall survival (OS)(Up to 24 Months after C-CAR039 infusion)
- The last of C-CAR039 in the peripheral blood after infusion (Tlast)(Up to 24 Months after C-CAR039 infusion)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaNon-Hodgkin's B-cell LymphomaNCT04693676First Affiliated Hospital of Zhejiang University17
已完成
1 期
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL SubjectsNon-Hodgkin's B-cell LymphomaNCT04317885Shanghai Tongji Hospital, Tongji University School of Medicine25
已完成
1 期
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's LymphomaB Cell Non-Hodgkin's LymphomaNCT05149391Peking University3
Unknown
1 期
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLRefractory or Relapsed B-cell Non-Hodgkin LymphomaNCT03299738Shanghai AbelZeta Ltd.10
Unknown
1 期
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT03751293Hebei Yanda Ludaopei Hospital10